United Therapeutics Corporation ($UTHR) Stock Forecast: Down 0.4% Today

What is United Therapeutics Corporation?

United Therapeutics (UTHR) is a pharmaceutical company specializing in innovative therapies for pulmonary arterial hypertension and orphan diseases. The stock showed a downward trend in the market today.

Why is United Therapeutics Corporation going down?

UTHR stock is down 0.4% on May 6, 2026 15:42

• Executives, including the CEO, CFO, and Chairperson, engaged in considerable insider selling, prompting investor concerns about the company's future.
• Despite positive recent developments like FDA designations for new products and higher price targets from analysts, ongoing insider selling could indicate potential overvaluation or internal issues.
• Insider selling, occurring as the stock nears its 52-week high, may have triggered additional selling pressure and a pessimistic investor outlook.
• Investors could perceive the insider selling as a lack of confidence in the company's ability to maintain its growth trajectory, resulting in a negative market response and the stock's decline.

UTHR Price Chart

UTHR Technical Analysis

UTHR News

Martine Rothblatt, United Therapeutics CEO, sells $5.48m in shares

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold approximately $5.48 million in shares on May 4, 2026. This transaction involved 9,500 shares and was executed under a pre-arranged 10b5-1 trading plan, coinciding with the exercise of stock options. The company has also seen recent positive developments, including an FDA designation for a new product and increased price targets from analysts.

https://m.investing.com/news/insider-trading-news/martine-rothblatt-united-therapeutics-ceo-sells-548m-in-shares-93CH-4660986?ampMode=1

New York State Teachers Retirement System Sells 3,936 Shares of United Therapeutics Corporation $UTHR

The New York State Teachers Retirement System reduced its stake in United Therapeutics Corporation (NASDAQ: UTHR) by 7.2% by selling 3,936 shares, now holding 50,872 shares valued at approximately $24.79 million. Brokerages have set an average price target of $601.50 with a "Moderate Buy" consensus rating for UTHR. However, insiders have been significant net sellers, offloading shares worth over $253 million in the last quarter, though they still own 10.30% of the stock.

https://www.marketbeat.com/instant-alerts/filing-new-york-state-teachers-retirement-system-sells-3936-shares-of-united-therapeutics-corporation-uthr-2026-05-03/

United Therapeutics chairperson & CEO Rothblatt sells $5.44m shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold approximately $5.44 million worth of shares on April 30, 2026, following the exercise of stock options. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The company has also seen recent positive developments including FDA designation for a liver device and favorable analyst ratings, with its stock trading near its 52-week high after a significant gain over the past year.

https://www.investing.com/news/insider-trading-news/united-therapeutics-chairperson--ceo-rothblatt-sells-544m-shares-93CH-4654508

United Therapeutics CFO James Edgemond sells $5.7m in stock

James Edgemond, CFO of United Therapeutics, sold 10,000 shares of company stock for approximately $5.73 million and simultaneously acquired 10,000 shares through option exercises for $1.35 million. These transactions, executed under a Rule 10b5-1 trading plan, occurred while the stock was near its 52-week high, with InvestingPro suggesting it is currently overvalued. The article also notes other recent company developments, including positive analyst ratings and advancements in pulmonary hypertension treatments.

https://www.investing.com/news/insider-trading-news/united-therapeutics-cfo-james-edgemond-sells-57m-in-stock-93CH-4654509

United Therapeutics chairperson & CEO Rothblatt sells $5.44m shares

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, sold approximately $5.44 million worth of shares on April 30, 2026, following the exercise of stock options. This transaction was executed under a pre-arranged trading plan, and she now directly holds over 40,000 shares and indirectly holds over 639,000 shares. The company has also seen recent positive developments including FDA designation for a liver device, multiple data presentations, and upgraded price targets from several financial analysts.

https://m.investing.com/news/insider-trading-news/united-therapeutics-chairperson--ceo-rothblatt-sells-544m-shares-93CH-4654508?ampMode=1

Trending Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 7.7% Today

Arista Networks Inc. ($ANET) Stock Forecast: Down 17.7% Today

Lam Research Corporation ($LRCX) Stock Forecast: Up 6.1% Today

Novavax Inc. ($NVAX) Stock Forecast: Up 19.1% Today

Ambarella Inc. ($AMBA) Stock Forecast: Up 5.1% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 5.4% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 5.2% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Down 6.7% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 5.5% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 15.1% Today

United Therapeutics Corporation Price History

06.00.2026 - UTHR Stock was up 5.0%

• Today's positive movement in UTHR stock is linked to the company's Chairperson and CEO speaking at the J.P. Morgan Healthcare Conference, underlining their dedication to innovation and addressing medical needs.
• Institutional investors, including Merit Financial Group LLC and Allspring Global Investments Holdings LLC, have increased their stake in the company, showing confidence in its future growth despite recent insider transactions.
• An analysis of the rotational strategy timing suggests short-term sentiment may be weak. However, the focus remains on UTHR's long-term potential and fundamentals, indicating investors are looking beyond immediate fluctuations.

02.03.2026 - UTHR Stock was down 5.2%

• The bearish movement in UTHR's stock could be attributed to the significant insider selling by the director, Christopher Causey, who exercised stock options and sold shares at a much higher price, possibly signaling lack of confidence in the stock's future performance.
• Despite positive news like successful Phase 3 trials and analyst price target increases, the insider selling coupled with concerns raised by institutional investors like Retirement Systems of Alabama might have contributed to the downward pressure on the stock.
• The proposed sale of additional shares through a stock option exercise by UTHR could have added to the selling pressure, creating a bearish sentiment among investors.
• The overall market reaction might have been influenced by profit-taking activities following the recent surge in stock price fueled by positive study results, as investors reevaluate the stock's valuation and potential downside risks highlighted.

10.02.2026 - UTHR Stock was up 5.6%

• UTHR experienced strong bullish movement following the announcement of a new $2 billion stock repurchase program, which includes a $1.5 billion Accelerated Share Repurchase (ASR) program with Citibank. This strategic move demonstrates confidence in the company's growth potential and belief in the undervaluation of its stock, leading to heightened investor confidence.
• The share repurchase agreements aim to decrease outstanding shares, potentially increasing the company's earnings per share and delivering value to shareholders. This capital allocation decision was well-received by investors, contributing to the rise in the stock price.
• Through these buyback programs, United Therapeutics is not only improving shareholder value but also utilizing its robust balance sheet to pursue long-term goals. The market's positive response to this shareholder-friendly initiative indicates optimism regarding UTHR's future performance.

03.02.2026 - UTHR Stock was down 5.3%

• Price targets for UTHR were raised by Jefferies and other firms after the positive Phase 3 trial results of its drug ralinepag for PAH treatment, showing a 55% reduction in clinical worsening risk.
• Despite the encouraging trial outcomes and analyst positivity, UTHR's stock saw a bearish movement, possibly attributed to profit-taking following recent gains.
• The company's recent product launches and advancements in xenotransplantation may have played a role in its robust stock performance over the previous year, although today's market movement could be influenced by broader market conditions or technical factors.
• Investors are advised to monitor UTHR's upcoming FDA submission for ralinepag and its revenue targets for potential future catalysts.

26.01.2026 - UTHR Stock was down 5.5%

• UTHR shares dropped by nearly 5% as the company missed Q4 revenue estimates while surpassing earnings expectations. This discrepancy could raise concerns among investors regarding the company's future growth trajectory.
• The company's operating margin declined year-on-year, indicating potential issues in cost management or operational efficiency that may have contributed to the market's negative response.
• Insider trading activities by the President and COO, involving the sale of shares at a specific price, could have impacted market sentiment, leading to a bearish trend as investors analyzed this move.
• Even though UTHR's Tyvaso product line and strategic efforts performed well, the market's attention on the revenue miss and insider trading overshadowed the positive financial results, causing a decline in the stock price.

25.01.2026 - UTHR Stock was up 11.2%

• The positive stock movement in UTHR is possibly linked to insider trading by President and COO Michael Benkowitz, who recently exercised stock options and sold shares at a noteworthy price, signaling confidence in the company's performance.
• Investors are looking forward to the upcoming Q4 earnings report, expecting a year-over-year revenue growth despite previous revenue estimate misses. This anticipation could potentially drive the stock price up.
• The FDA's recent approval of Tyvaso dry powder inhaler for treating PAH and PH-ILD, a product developed by United Therapeutics, may have influenced investor sentiment positively. This showcases the company's dedication to innovation and addressing unmet medical needs in the market.

30.02.2026 - UTHR Stock was up 0.5%

• The positive phase 3 study results for nebulized Tyvaso and the introduction of a new $2 billion stock repurchase program have driven the bullish movement in United Therapeutics' stock, receiving favorable attention from analysts and investors.
• Initial concerns surrounding insider selling by company executives, including the CEO, Chairperson, COO, and CFO, were potentially offset by increased institutional investor stake from Wealth Enhancement Advisory Services LLC and Wedge Capital Management L L P NC.
• A price target raise by Cantor Fitzgerald to $625 with an "Overweight" rating has further bolstered investor confidence in the company, in anticipation of the upcoming TETON-1 clinical trial for idiopathic pulmonary fibrosis treatment.
• While revenue fell short of estimates, a strong performance in earnings per share during Q4, along with strategic initiatives and a positive outlook, likely played a role in the recent bullish trend of United Therapeutics' stock.

06.04.2026 - UTHR Stock was down 0.4%

• Executives, including the CEO, CFO, and Chairperson, engaged in considerable insider selling, prompting investor concerns about the company's future.
• Despite positive recent developments like FDA designations for new products and higher price targets from analysts, ongoing insider selling could indicate potential overvaluation or internal issues.
• Insider selling, occurring as the stock nears its 52-week high, may have triggered additional selling pressure and a pessimistic investor outlook.
• Investors could perceive the insider selling as a lack of confidence in the company's ability to maintain its growth trajectory, resulting in a negative market response and the stock's decline.